Tyra Biosciences Inc TYRA
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2021-09-15 |
| Shares Out. | 59,470,000 |
| Website | tyra.bio/ ↗ |
| Phone | 16197284760 |
| Employees | 87 |
| Net Income | -$39.3M |
| Free Cash Flow | -$102.5M |
| Total Assets | $412.0M |
| Total Liabilities | $24.5M |
| Equity | $387.6M |
About Tyra Biosciences Inc
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
Tyra Biosciences Inc is a publicly traded company under the ticker symbol TYRA on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
22 analysts (2026-07-01)